As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Jerry Hughes has selected topical, interesting papers for your perusal that also include interesting articles from the emerging economic regions and publications on COVID-19 and CML.

Read Professor Hughes' CML publications of the month: July 2021

Clinical papers

• Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukemia patients
  Rousselot P et al. Br J Haematol, July 2021
• Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity
  Janssen L et al. Haematologica, July 2021 – open access publication
• Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: A Review
  Yassin MA et al. Surv Ophthalmol, July 2021 (epub ahead of print) – open access publication
• Arterial hypertension assessment in a population with chronic myeloid leukemia
  Roa-Chamorro R et al. Sci Rep, July 2021 – open access publication
• Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia in tyrosine kinase inhibitors
  Rodia R et al. J Endocrinol Invest, July 2021 (epub ahead of print) – open access publication
• Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: A Report from the Nagasaki CML Study Group
  Chiwata M et al. Intern Med, July 2021 – open access publication
• Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs. imatinib among patients with chronic myeloid leukemia: A systematic review and meta-analysis
  Wang Z et al. JAMA Netw open, July 2021 – open access publication
• Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib
  Marcé S et al. J Clin Med, July 2021 – open access publication

Scientific papers

• DNA methylation and intra-clonal heterogeneity: The chronic myeloid leukemia model
  Lebecque B et al. Cancers(Basel), July 2021 – open access publication
  
• HNRNPH1 is a novel regulator of cellular proliferation and disease progression in chronic myeloid leukemia
  Liu M et al. Front Oncol, July 2021 – open access publication
• Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation and changes following interferon treatment
  Kong J et al. Ann Hematol, July 2021 (epub ahead of print)
• Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukemia at diagnosis and early follow-up
  Romzova M et al. Br J Haematol, July 2021 (epub ahead of print)
• Role of lysophospholipid metabolism in chronic myelogenous leukemia stem cells
  Naka K. Cancers(Basel), July 2021 – open access publication

Pediatric papers

• A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety
  Hijiya N et al. Blood Adv, July 2021 open access publication

ERSAP papers

• Spectrum of BCR-ABL mutations and treatment outcomes in Ethiopian Imatinib-resistant patients with chronic myeloid leukemia
  Tadesse F et al. JCO Glob Oncol, July 2021 - open access publication
• Long-term outcome of tyrosine kinase treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic-phase
  Zheng YZ et al. Chin Med J (Engl), July 2021 - open access publication

COVID-19 papers

COVID-19 and CML

• COVID-19 in chronic myeloid leukemia patients in Latin America
  Pagnano KB et al. Leuk Lymphoma, July 2021 (epub ahead of print)

COVID-19 and haematological malignancies / cancer

• Preclinical evaluation of imatinib does not support its use as an antiviral drug against SARS-CoV-2
  Touret F et al. Antiviral Res, July 2021 (epub ahead of print) – open access publication
• COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
  Passamonti F et al. Br J Haematol, July 2021 (epub ahead of print) – open access publication